Abiraterone Acetate (Zytiga®)

 
Common name: Abiraterone Acetate
Brand name: Zytiga®


What is Abiraterone Acetate?

Abiraterone Acetate is a drug used to treat advanced prostate cancer (metastatic castrate resistant prostate cancer). Abiraterone acetate blocks the production of testosterone to stop the spread and growth of prostate cancer cells.

Abiraterone Acetate is used in combination with a corticosteroid (such as prednisone) and has been approved for the following uses:
  • It is given to men who previously received docetaxel chemotherapy after failure of androgen deprivation therapy.
  • It is also given to men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.


How is Abiraterone Acetate administered?

Abiraterone Acetate is administered orally as a tablet.


What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received abiraterone acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Diarrhea
  • Frequent urination
  • High blood pressure
  • Hot flashes
  • Joint pain
  • Low potassium (hypokalemia)
  • Muscle aches
  • Upset stomach

Is Abiraterone Acetate covered in my province or territory?

Abiraterone acetate is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Ontario
  • Quebec
  • Saskatchewan
Abiraterone acetate is not covered by provincial/territorial drug programs in:
  • Manitoba
  • Prince Edward Island
  • Nunavut
  • Northwest Territories
  • Yukon
The pan-Canadian Oncology Drug Review (pCODR) recommends funding abiraterone acetate (zytiga®).
To read pCODRs full recommendation, please click here.

For more information on pCODR, please visit www.pcodr.ca
 


Last Reviewed: July 2017

Prostate Cancer Awareness Month

Donate Now!


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Prostate Cancer Canada launches first national program in radionuclide therapy

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation.
More

Honouring dad this Father’s Day the Canadian way: In plaid

TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer.
More

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.
More


Click here for news archive